Is Viking Therapeutics the Best Biotech Stock for You?
Could 2024 be a breakout year for Viking Therapeutics (NASDAQ: VKTX)? The mid-cap biotech has generated more positive headlines than most of its peers. Excitement is through the roof. Due to crucial clinical progress, Viking Therapeutics' shares have tripled this year.
Biotech investors have noticed, but many remain on the sidelines wondering whether Viking is the right choice for them -- or whether the stock is a one-hit (or one-year) wonder. Let's discuss the drugmaker's prospects and determine whether it is worth investing in this high-flying company.
Relatively small clinical-stage biotechs have incredible upside potential. Imagine if you had invested in Vertex Pharmaceuticals 30 years ago. Is it unfair to compare Viking to such an established and prominent player in the biotech industry? Maybe, but it's worth noting that it isn't just any other mid-cap biotech.
Source Fool.com
